(VIANEWS) – NICE Ltd (NICE), Red Rock Resorts (RRR), Crane Company (CR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NICE Ltd (NICE)
14.8% sales growth and 10.56% return on equity
NICE Ltd., together with its subsidiaries, provides cloud platforms for AI-driven digital business solutions worldwide. It offers CXone, a cloud native open platform; Enlighten, an AI engine for the customer engagement market; and smart self service enable organizations to address consumers' needs; and journey orchestration solutions that empower organizations to connect and route customers to deal with the customer's request, and connects them using real time AI-based routing. The company provides smart self service solutions that empower organizations to build intelligent automated conversations based on data; and prepared agent solutions and tools enable contact center agents to guide and alert them in real time; provides solutions that help organizations to record structured and unstructured customer interaction and transaction data; and NICE Evidencentral, an digital evidence management platform for public safety emergency communications, law enforcement, and criminal justice helps agencies. In addition, it offers X-Sight, is an open and flexible AI-cloud platform for financial crime and compliance; Xceed, a cloud platform for comprehensive AML and fraud prevention for small and mid-sized organizations; data intelligence solutions that enable organizations to turn raw data into comprehensive actionable intelligence to prevent and detect financial crimes; AI and analytics technologies to detect and prevent financial crimes in real-time; money laundering and fraud prevention solutions that help organizations adhere to capital markets compliance and anti-money laundering compliance regulations; intelligent investigations solutions; and self-service solutions that provide organizations with customization and self-development capabilities. The company was formerly known as NICE-Systems Ltd. and changed its name to NICE Ltd. in June 2016. NICE Ltd. was founded in 1986 and is headquartered in Ra'anana, Israel.
Earnings Per Share
As for profitability, NICE Ltd has a trailing twelve months EPS of $5.11.
PE Ratio
NICE Ltd has a trailing twelve months price to earnings ratio of 45.4. Meaning, the purchaser of the share is investing $45.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.56%.
Moving Average
NICE Ltd’s worth is below its 50-day moving average of $237.98 and way above its 200-day moving average of $205.59.
Sales Growth
NICE Ltd’s sales growth is 14.6% for the ongoing quarter and 14.8% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.6%, now sitting on 2.38B for the twelve trailing months.
2. Red Rock Resorts (RRR)
12.7% sales growth and 244.65% return on equity
Red Rock Resorts, Inc., through its interest in Station Holdco and Station LLC, develops and operates casino and entertainment properties in the United States. It operates through two segments, Las Vegas Operations and Native American Management. The company owns and operates 9 gaming and entertainment facilities, and 10 smaller casinos in the Las Vegas regional market. In addition, it manages Graton Resort & Casino in northern California. As of December 31, 2021, it operated approximately 13,894 slot machines, 240 table games, and 3,081 hotel rooms in the Las Vegas market. The company was formerly known as Station Casinos Corp. and changed its name to Red Rock Resorts, Inc. in January 2016. Red Rock Resorts, Inc. was incorporated in 1976 and is based in Las Vegas, Nevada.
Earnings Per Share
As for profitability, Red Rock Resorts has a trailing twelve months EPS of $2.94.
PE Ratio
Red Rock Resorts has a trailing twelve months price to earnings ratio of 18.46. Meaning, the purchaser of the share is investing $18.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 244.65%.
Sales Growth
Red Rock Resorts’s sales growth is 12.9% for the ongoing quarter and 12.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.84%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.8%, now sitting on 1.72B for the twelve trailing months.
Volume
Today’s last reported volume for Red Rock Resorts is 185370 which is 57.74% below its average volume of 438680.
3. Crane Company (CR)
9.9% sales growth and 12.42% return on equity
Crane Co. manufactures and sells engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. The company's Fluid Handling segment offers on/off valves and related products for the chemical, oil and gas, power, and general industrial end markets; valves and related products for the non-residential construction, general industrial, and municipal markets; fluid control instrumentation and sampling solutions; and pumps and related products for water and wastewater applications in industrial, municipal, commercial, and military markets. This segment sells its products under the Crane, Saunders, Jenkins, Pacific, Xomox, Krombach, DEPA, ELRO, REVO, Flowseal, Centerline, Resistoflex, Duochek, Barksdale, Westlock, WTA, HOKE, DOPAK, Stockham, Wask, Viking Johnson, IAT, Hattersley, NABIC, Sperryn, Wade, Deming, Weinman, Burks, and Barnes brands. Its Payment & Merchandising Technologies segment provides technology payment acceptance and dispensing products to original equipment manufacturers and for vertical markets; currency handling and processing systems, cash and cashless payment and merchandising solutions, equipment service solutions, and connected managed service solutions. The company's Aerospace & Electronics segment offers original equipment and aftermarket parts under the Hydro-Aire, ELDEC, Lear Romec, P.L. Porter, Keltec, Interpoint, Signal Technology, Merrimac Industries, and Polyflon brands to commercial and military aerospace, and defense and space markets. Its Engineered Materials segment provides fiberglass-reinforced plastic panels and coils primarily for use in the manufacturing of recreational vehicles, truck bodies, and trailers, as well as used in commercial and industrial building construction. Crane Co. was founded in 1855 and is based in Stamford, Connecticut.
Earnings Per Share
As for profitability, Crane Company has a trailing twelve months EPS of $3.68.
PE Ratio
Crane Company has a trailing twelve months price to earnings ratio of 39.2. Meaning, the purchaser of the share is investing $39.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.42%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 31, 2024, the estimated forward annual dividend rate is 0.82 and the estimated forward annual dividend yield is 0.57%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10%, now sitting on 2.14B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 11.8% and 24.3%, respectively.
Sales Growth
Crane Company’s sales growth is 10.4% for the ongoing quarter and 9.9% for the next.
4. American Express (AXP)
9.2% sales growth and 32.85% return on equity
American Express Company, together with its subsidiaries, operates as integrated payments company in the United States, Europe, the Middle East and Africa, the Asia Pacific, Australia, New Zealand, Latin America, Canada, the Caribbean, and Internationally. It operates through four segments: U.S. Consumer Services, Commercial Services, International Card Services, and Global Merchant and Network Services. The company's products and services include credit card, charge card, banking, and other payment and financing products; network services; expense management products and services; and travel and lifestyle services. It also provides merchant acquisition and processing, servicing and settlement, point-of-sale marketing, and information products and services for merchants; and fraud prevention services, as well as the design and operation of customer loyalty programs. In addition, the company operates lounges at airports under Centurion Lounge brand name. It sells its products and services to consumers, small businesses, mid-sized companies, and large corporations through mobile and online applications, affiliate marketing, customer referral programs, third-party service providers and business partners, direct mail, telephone, in-house sales teams, and direct response advertising. American Express Company was founded in 1850 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, American Express has a trailing twelve months EPS of $11.22.
PE Ratio
American Express has a trailing twelve months price to earnings ratio of 19.45. Meaning, the purchaser of the share is investing $19.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.85%.
Yearly Top and Bottom Value
American Express’s stock is valued at $218.20 at 06:22 EST, below its 52-week high of $240.55 and way above its 52-week low of $140.91.
Volume
Today’s last reported volume for American Express is 1867650 which is 39.87% below its average volume of 3106400.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 4, 2024, the estimated forward annual dividend rate is 2.8 and the estimated forward annual dividend yield is 1.21%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 13.1% and 0.3%, respectively.
5. Incyte Corporation (INCY)
8.9% sales growth and 15.13% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $2.65.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 20.32. Meaning, the purchaser of the share is investing $20.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.13%.
Yearly Top and Bottom Value
Incyte Corporation’s stock is valued at $53.85 at 06:22 EST, way under its 52-week high of $67.36 and above its 52-week low of $50.27.
Volume
Today’s last reported volume for Incyte Corporation is 683729 which is 59.07% below its average volume of 1670830.
Sales Growth
Incyte Corporation’s sales growth is 5.7% for the current quarter and 8.9% for the next.
Moving Average
Incyte Corporation’s value is under its 50-day moving average of $55.53 and below its 200-day moving average of $58.69.
6. International General Insurance Holdings Ltd. (IGIC)
8% sales growth and 24.85% return on equity
International General Insurance Holdings Ltd. provides specialty insurance and reinsurance solutions worldwide. The company operates through three segments: Specialty Long-tail, Specialty Short-tail, and Reinsurance segments. It offers a portfolio of specialty lines insurance products and services for energy, property, construction and engineering, ports and terminals, general aviation, political violence, casualty, financial institutions, marine liability, and treaty reinsurance. The company was founded in 2001 and is based in Amman, Jordan.
Earnings Per Share
As for profitability, International General Insurance Holdings Ltd. has a trailing twelve months EPS of $2.55.
PE Ratio
International General Insurance Holdings Ltd. has a trailing twelve months price to earnings ratio of 5.29. Meaning, the purchaser of the share is investing $5.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.3%, now sitting on 471.96M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 28, 2024, the estimated forward annual dividend rate is 0.04 and the estimated forward annual dividend yield is 0.3%.
Yearly Top and Bottom Value
International General Insurance Holdings Ltd.’s stock is valued at $13.48 at 06:22 EST, below its 52-week high of $14.14 and way above its 52-week low of $8.05.
7. Chimera Investment Corporation (CIM)
6.7% sales growth and 4.83% return on equity
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in a portfolio of mortgage assets, including residential mortgage loans, agency and non-agency residential mortgage-backed securities, agency mortgage-backed securities secured by pools of commercial mortgage loans, and other real estate related securities. It has elected to be taxed as a REIT and would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its shareholders. The company was incorporated in 2007 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Chimera Investment Corporation has a trailing twelve months EPS of $0.23.
PE Ratio
Chimera Investment Corporation has a trailing twelve months price to earnings ratio of 20.48. Meaning, the purchaser of the share is investing $20.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.83%.
Moving Average
Chimera Investment Corporation’s worth is above its 50-day moving average of $4.32 and under its 200-day moving average of $5.00.
Revenue Growth
Year-on-year quarterly revenue growth declined by 60%, now sitting on 226.02M for the twelve trailing months.
8. Kamada Ltd. (KMDA)
5.1% sales growth and 3.94% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.15.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 34.33. Meaning, the purchaser of the share is investing $34.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.94%.
Volume
Today’s last reported volume for Kamada Ltd. is 5461 which is 74.7% below its average volume of 21587.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 250% and 50%, respectively.
